The Manufacturers Life Insurance Company Purchases New Position in Bicara Therapeutics Inc. $BCAX

Posted by Brenda Bartman on Sep 3rd, 2026

The Manufacturers Life Insurance Company acquired a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX – Free Report) in the 2nd quarter, Holdings Channel reports. The fund acquired 72,174 shares of the company’s stock, valued at approximately $2,143,000.

Several other hedge funds also recently made changes to their positions in BCAX. Legal & General Group Plc increased its position in shares of Bicara Therapeutics by 64.1% during the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after purchasing an additional 1,233 shares in the last quarter. Larson Financial Group LLC boosted its position in shares of Bicara Therapeutics by 1,015.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after purchasing an additional 3,595 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of Bicara Therapeutics by 419.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after purchasing an additional 3,866 shares during the period. Caitong International Asset Management Co. Ltd grew its stake in Bicara Therapeutics by 385.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock worth $97,000 after buying an additional 4,585 shares during the last quarter. Finally, New York State Common Retirement Fund grew its stake in Bicara Therapeutics by 87.5% during the 4th quarter. New York State Common Retirement Fund now owns 7,500 shares of the company’s stock worth $126,000 after buying an additional 3,500 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on BCAX shares. Guggenheim started coverage on Bicara Therapeutics in a research note on Monday, May 11th. They issued a “buy” rating and a $42.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Bicara Therapeutics in a research report on Wednesday, May 27th. BTIG Research lifted their target price on shares of Bicara Therapeutics from $28.00 to $39.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. BMO Capital Markets assumed coverage on shares of Bicara Therapeutics in a research report on Tuesday, August 18th. They issued an “outperform” rating and a $35.00 price target for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Monday, July 6th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Bicara Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $32.64.

Check Out Our Latest Stock Report on Bicara Therapeutics

Bicara Therapeutics Stock Up 0.6%

Shares of BCAX stock opened at $23.56 on Thursday. The stock has a market capitalization of $1.56 billion, a PE ratio of -7.60 and a beta of -0.82. Bicara Therapeutics Inc. has a 52-week low of $10.30 and a 52-week high of $30.99. The stock’s 50-day moving average price is $26.61 and its 200 day moving average price is $22.61.

Bicara Therapeutics (NASDAQ:BCAX – Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.82) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.82). Analysts expect that Bicara Therapeutics Inc. will post -3.45 earnings per share for the current fiscal year.

Insider Transactions at Bicara Therapeutics

In related news, CEO Claire Mazumdar sold 10,000 shares of Bicara Therapeutics stock in a transaction on Monday, August 10th. The shares were sold at an average price of $27.98, for a total value of $279,800.00. Following the transaction, the chief executive officer directly owned 362,152 shares in the company, valued at $10,133,012.96. This trade represents a 2.69% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ryan Cohlhepp sold 18,750 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $27.98, for a total transaction of $524,625.00. Following the completion of the transaction, the chief operating officer directly owned 181,641 shares in the company, valued at $5,082,315.18. This represents a 9.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 108,000 shares of company stock worth $3,079,236 over the last 90 days. 13.80% of the stock is currently owned by insiders.

Bicara Therapeutics Company Profile

(Free Report)

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.